Overcoming problems with adherence to osteoporosis medication.

[en] Nonadherence to pharmacological treatment in osteoporosis is a well-recognized problem. As in other chronic diseases, adherence to osteoporosis treatment is poor, resulting in enormous burden on patients and healthcare resources. Most importantly, low adherence rates consistently result in increased rates of fractures. However, it seems that efforts to evaluate and improve rates of both compliance and persistence are increasing. The extension of dosing intervals may be an element, among others, allowing improvements in therapeutic adherence. Improved patient education, enhancing healthcare provider-patients interaction, taking into account patient's preferences and involving them in treatment decisions may improve adherence.

Disciplines :

General & internal medicine

Author, co-author :

Rabenda, Véronique ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé

Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé

Language :

English

Title :

Overcoming problems with adherence to osteoporosis medication.

Publication date :

2010

Journal title :

Expert Review of Pharmacoeconomics and Outcomes Research

ISSN :

1473-7167

eISSN :

1744-8379

Publisher :

Taylor & Francis, United Kingdom

Volume :

Issue :

Pages :

677-89

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 21 March 2011

Statistics

Number of views

96 (3 by ULiège)

Number of downloads

6 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Reginster JY, Lecart MP. Treatment of osteoporosis with bisphosphonates - do compliance and persistence matter? Bus. Brief Long-Term Healthcare 5, 65-68 (2004).
Burrell A, Wong P, Ollendorf D et al. Defining compliance, adherence and persistence: ISPOR Special Interest Working Group. Value Health 8, A194-A195 (2005).
Lekkerkerker F, Kanis JA, Alsayed N et al. Group for the Respect of Ethics and Excellence in Science (GREES). Adherence to treatment of osteoporosis: a need for study. Osteoporos. Int. 18, 1311-1317 (2007).
Black DM, Cummings SR, Karpf DB et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348, 1535-1541 (1996).
Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282, 1344-1352 (1999).
Reginster JY, Minne HW, Sorensen OH et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos. Int. 11, 83-91 (2000).
McClung MR, Geusens P, Miller PD et al. Effects of risedronate on the risk of hip fracture in elderly women. Hip Interventiopn Program Study Group. N. Engl. J. Med. 344, 333-340 (2001).
Chesnut CH 3rd, Skag A, Christiansen C et al. Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. Bone Miner. Res. 19, 1241-1249 (2004).
Kothawala P, Badamgarav E, Ryu S, Miller R, Halbert RJ. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin. Proc. 82, 1493-1501 (2007).
Rabenda V, Hiligsmann M, Reginster JY. Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin. Pharmacother. 10, 2303-2315 (2009).
Siris E, Selby P, Saag K, Borgstrom F, Herings R, Silverman S. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am. J. Med. 122, S3-S13 (2009).
Blouin J, Dragomir A, Ste-Marie LG, Fernandes JC, Perreault S. Discontinuation of antiresorptive therapies: a comparison between 1998-2001 and 2002-2004 among osteoporotic women. J. Clin. Endocrinol. Metab. 92, 887-894 (2007).
Brookhart MA, Avorn J, Katz JN et al. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am. J. Med. 120, 251-256 (2007).
Lo JC, Pressman AR, Omar MA, Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos. Int. 17, 922-928 (2006).
Kendler D, Kung AW, Fuleihan G et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 48, 243-251 (2004).
Reginster JY, Rabenda V. Patient preference in the management of postmenopausal osteoporosis with isphosphonates. Clin. lnterv. Aging 1, 415-423 (2006).
Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin. Ther. 24, 1871-1886 (2002).
Baroutsou B, Babiolakis D, Stamatiadou AE et al. Patient compliance and preference of alendronate once weekly administration in comparison with daily regimens for osteoporotic postmenopausal women. Ann. Rheum. Dis. 63(Suppl. 1), 455 (2004).
Weiss M, Vered I, Foldes AJ, Cohen YC, Shamir-Elron Y, Ish-Shalom S. Treatment preference and tolerability with alendronate once weekly over a 3-month period: an Israeli multi-center study. Aging Clin. Exp. Res. 17, 143-149 (2005).
Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr. Med. Res. Opin. 21, 1453-1460 (2005).
Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin. Proc. 80, 856-861 (2005).
Cramer JA, Lynch NO, Gaudin AF, Walker M, Cowell W. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin. Ther. 28, 1686-1694 (2006).
Ettinger MP, Gallagher R, MacCosbe PE. Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr. Pract. 12, 522-528 (2006).
Gold DT, Safi W, Trinh H. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr. Med. Res. Opin. 22, 2383-2391 (2006).
Weiss TW, McHorney CA. Osteoporosis medication profile preference: results from the PREFER-US study. Health Expect. 10, 211-223 (2007).
Weiss TW, Gold DT, Silverman SL, McHorney CA. An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study. Curr. Med. Res. Opin. 22, 949-960 (2006).
Duarte JW, Bolge SC, Sen SS. An evaluation of patients' preferences for osteoporosis medications and their attributes: the PREFER-International study. Clin. Ther. 29, 488-503 (2007).
Richards JB, Cherkas LF, Spector TD. An analysis of which anti-osteoporosis therapeutic regimen would improve compliance in a population of elderly adults. Curr. Med. Res. Opin. 23, 293-299 (2007).
Keen R, Jodar E, Iolascon G et al. European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency. Curr. Med. Res. Opin. 22, 2375-2381 (2006).
Emkey R, Koltun W, Beusterien K et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr. Med. Res. Opin. 21, 1895-1903 (2005).
Hadji P, Benhamou CL, Devas V et al. Women with postmenopausal osteoporosis prefer once-monthly oral ibandronate to weekly oral alendronate: results of BALTO II. Osteoporos. Int. 17(Suppl. 1), S69 (2006).
Cotte FE, Fardellone P, Mercier F, Gaudin AF, Roux C. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos. Int. 21, 145-155 (2010).
Lewiecki EM, Babbitt AM, Piziak VK et al. Adherence to and gastrointestinal tolerability of monthly oral and quarterly intravenous ibandronate in women with previous intolerance in oral bisphosphonates: a 12-month, open-label prospective evaluation. Clin. Ther. 30, 605-621 (2008).
McClung M, Recker R, Miller P et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 41, 122-128 (2007).
Saag K, Lindsay R, Kriegman A et al. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 40, 1238-1243 (2007).
Carnevale V, Nieddu L, Romagnoli E et al. Osteoporosis intervention in ambulatory patients with previous hip fracture: a multicentric, nationwide Italian survey. Osteoporos. Int. 17, 478-483 (2006).
Petrella RJ, Jones TJ. Do patients receive recommended treatment of osteoporosis following hip fracture in primary care? BMC Fam. Pract. 7, 31 (2006).
Rabenda V, Vanoverloop J, Fabri V et al. Low incidence of anti-osteoporosis treatment after hip fracture. J. Bone Joint Surg. Am. 90, 2142-2148 (2008).
Tosteson AN, Grove MR, Hammond CS et al. Early discontinuation of treatment for osteoporosis. Am. J. Med. 115, 209-216 (2003).
Rossini M, Bianchi G, Di Munno O et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos. Int. 17, 914-921 (2006).
Blouin J, Dragomir A, Moride Y et al. Impact of non-compliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women. Br. J. Clin. Pharmacol. 66, 117-127 (2008).
Grant AM, Avenell A, Campbell MK et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 365, 1621-1628 (2005).
Jackson RD, LaCroix AZ, Gass M et al. Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of fractures. N. Engl. J. Med. 354, 669-683 (2006).
Antoniucci DM, Vittinghoff E, Palermo L, Black DM, Sellmeyer DE. Vitamin D insufficiency does not affect response of bone mineral density to alendronate. Osteoporos. Int. 20, 1259-1266 (2009).
Arden NK, Earl S, Fisher DJ, Cooper C, Carruthers S, Goater M. Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporos. Int. 17, 1626-1629 (2006).
Ziller V, Zimmermann SP, Kalder M et al. Adherence and persistence in patients with severe osteoporosis treated with teriparatide. Curr. Med. Res. Opin. 26, 675-681 (2010).
Lewiecki EM. Denosumab update. Curr. Opin. Rheumatol. 21, 369-373 (2009).
Kendler DL, Bessette L, Hill CD et al. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos. Int. 21, 837-846 (2010).
Reginster J-Y, Seeman E, De Vernejoul MC et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab. 90, 2816-2822 (2005).
Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med. 350, 459-468 (2004). (Pubitemid 38133766)
Neuprez A, Hiligsmann M, Scholtissen S, Bruyere O, Reginster JY. Strontium ranelate: the first agent of a new therapeutic class in osteoporosis. Adv. Ther. 25, 1235-1256 (2008).
Reginster JY, Bruyere O, Sawicki A et al. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. Bone 45, 1059-1064 (2009).
Rabenda V, Reginster JY. Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteoporotic fractures. Osteoporos. Int. 21(12), 1993-2002 (2010).
Breart G, Audran M, Brandi ML et al. Good safety and persistence of strontium ranelate in a prospective observational cohort study. Osteoporos. Int. 20(Suppl. 1), S94 (2009) (Abstract P273).
Yood RA, Emani S, Reed JI et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos. Int. 14, 965-968 (2003).
Sebaldt RJ, Shane LG, Pham B et al. Impact of non-compliance and non-persistence with daily bisphosphonates on longer-term effectiveness outcomes in patients with osteoporosis treated in tertiary specialist care. J. Bone Miner. Res. 19(Suppl. 1), S445 (2004).
Eastell R, Garnero P, Vrijens B et al. Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Calcif. Tissue Int. 72, 408 (2003).
Rabenda V, Mertens R, Fabri V et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos. Int. 19, 811-818 (2008).
Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos. Int. 19, 511-517 (2008).
van den Boogaard CH, Breekveldt-Postma NS, Borggreve SE et al. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr. Med. Res. Opin. 22, 1757-1764 (2006).
Siris ES, Harris ST, Rosen CJ et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin. Proc. 81, 1013-1022 (2006).
Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos. Int. 18, 271-277 (2007).
Briesacher BA, Andrade SE, Yood RA, Kahler KH. Consequences of poor compliance with bisphosphonates. Bone 41, 882-887 (2007).
Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos. Int. 21(11), 1943-1951 (2009).
Wilkes MM, Navickis RJ, Chan WW, Lewiecki EM. Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/ persistent postmenopausal women in clinical practice versus randomized controlled trials. Osteoporos. Int. 21, 679-688 (2010).
Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 370, 657-666 (2007).
Reginster JY. Calcium and vitamin D for osteoporotic fracture risk. Lancet 370, 632-633 (2007).
Bronder E, Klimpel A. Unused drugs returned to the pharmacy - new data. Int. J. Clin. Pharmacol. Ther. 39, 480-483 (2001).
Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch. Intern. Med. 150, 841-845 (1990).
Berg JS, Dischler J, Wagner DJ et al. Medication compliance: a healthcare problem. Ann. Pharmacother. 27(9 Suppl.), S1-S24 (1993).
McCombs JS, Thibaud P, McLaughlin-Miley C et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48, 271-287 (2004).
Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38, 922-928 (2006).
Sullivan S, Kreling D, Hazlet TH. Non-compliance with medication regimens and subsequent hospitalizations: a literature analysis and cost of hospitalization estimate. J. Res. Pharm. Econ. 2, 19-33 (1990).
Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am. J. Med. 102, 43-49 (1997).
Sunyecz JA, Mucha L, Baser O, Barr CE, Amonkar MM. Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporos. Int. 19, 1421-1429 (2008).
Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY. Potential clinical and economic impact of nonadherence with osteoporosis medication. Calcif. Tissue Int. 86, 202-210 (2010).
Sheehy O, Kindundu C, Barbeau M, LeLorier J. Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures. Osteoporos. Int. 20, 1583-1594 (2009).
Simpson SH, Eurich DT, Majumdar SR et al. A meta-analysis of the association between adherence to drug therapy and mortality. Br. Med. J. 333, 15 (2006).
Ettinger B, Pressman AR, Schein J et al. Alendronate use among 812 women: prevalence of gastrointestinal complaints, non-compliance with patient's instructions and discontinuation. J. Manag. Care Pharm. 4, 488-492 (1998).
Aki S, Eskiyurt N, Akarirmak U et al. Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis. Yonsei Med. J. 44, 961-967 (2003).
McHorney CA, Schousboe JT, Cline RR, Weiss TW. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Curr. Med. Res. Opin. 23, 3137-3152 (2007).
Woo C, Gao G, Wade S, Hochberg MC. Gastrointestinal side effects in postmenopausal women using osteoporosis therapy: 1-year findings in the POSSIBLE US study. Curr. Med. Res. Opin.. 26, 1003-1009 (2010).
Miller NH. Compliance with treatment regimens in chronic symptomatic diseases. Am. J. Med. 102, 43-49 (1997).
Kennedy J, Teleu I, Mackay K. Unfilled prescriptions of Medicare beneficiaries: prevalence, reasons, and types of medicines prescribed. J. Manag. Care Pharm. 14, 553-560 (2008).
Weiss TW, Henderson SC, McHorney CA, Cramer JA. Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Curr. Med. Res. Opin. 23, 2193-2203 (2007).
Solomon DH, Avorn J, Katz JN et al. Compliance with osteoporosis medications. Arch. Intern. Med. 165, 2414-2419 (2005).
Lo JC, Pressman AR, Omar MA, Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos. Int. 17, 922-928 (2006).
Carr AJ, Thompson PW, Cooper C. Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos. Int. 17, 1638-1644 (2006).
Yood RA, Mazor KM, Andrade SE, Emani S, Chan W, Kahler KH. Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J. Gen. Intern. Med. 23, 1815-1821 (2008).
Curtis JR, Xi J, Westfall AO et al. Improving the prediction of medication compliance: the example of bisphoshponates for osteoporosis. Med. Care 47, 334-341 (2009).
Gleeson T, Iversen MD, Avorn J et al. Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos. Int. 20, 2127-2134 (2009).
Cook PF, Emiliozzi S, McCabe MM. Telephone counselling to improve osteoporosis treatment adherence: an effectiveness study in community practice settings. Am. J. Med. Qual. 22, 445-456 (2007).
DiIorio C, McCarty F, Resnicow K et al. Using motivational interviewing to promote adherence to antiretroviral medications: a randomized controlled study. AIDS Care 20, 273-283 (2008).
Golin CE, Earp J, Tien HC, Stewart P, Porter C, Howie L. A 2-arm, randomized, controlled trial of a motivational interviewing-based intervention to improve adherence to antiretroviral therapy (ART) among patients failing or initiating ART. J. Acquir. Immune Defic. Syndr. 42, 42-51 (2006).
Schmaling KB, Blume AW, Afari N et al. A randomised controlled pilot study of motivational interviewing to change attitudes about adherence to medications for asthma. J. Clin. Psychol. Med. Settings 8, 167-172 (2001).
Ogedegbe G, Chaplin W, Schoenthaler A et al. A practice-based trial of motivational interviewing and adherence in hypertensive African Americans. Am. J. Hypertens. 21, 1137-1143 (2008).
McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 288, 2868-2879 (2002).
Belcon MC, Haynes RB, Tugwell P. A critical review of compliance studies in rheumatoid arthritis. Arthritis Rheum. 27, 1227-1233 (1984).
Cuddihy MT, Amadio PC, Gabriel SE, Pankratz VS, Kurland RL, Melton LJ 3rd. A prospective clinical practice intervention to improve osteoporosis management following distal forearm fracture. Osteoporos. Int. 15, 695-700 (2004).
Sedlak CA, Doheny MO, Jones SL. Osteoporosis education programs: changing knowledge and behaviors. Public Health Nurs. 17, 398-402 (2000).
Estok PJ, Sedlak CA, Doheny MO, Hall R. Structural model for osteoporosis preventing behavior in postmenopausal women. Nurs. Res. 56, 148-158 (2007).
Rolnick SJ, Kopher R, Jackson J, Fischer LR, Compo R. What is the impact of osteoporosis education and bone mineral density testing for postmenopausal women in a managed care setting? Menopause 8, 141-148 (2001).
Guilera M, Fuentes M, Grifols M, Ferrer J, Badia X. Does an educational leaflet improve self-reported adherence to therapy in osteoporosis? The OPTIMA study. Osteoporos. Int. 17, 664-671 (2006).
Cooper A, Drake J, Brankin E. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int. J. Clin. Pract. 60, 896-905 (2006).
Briot K, Ravaud P, Dargent-Molina P, Zylberman M, Liu-Leage S, Roux C. Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporos. Int. 20, 625-630 (2009).
Nielsen D, Ryg J, Nielsen W, Knold B, Nissen N, Brixen K. Patient education in groups increases knowledge of osteoporosis and adherence to treatment: a two-year randomized controlled trial. Patient Educ. Couns. 81(2), 155-160 (2010).
Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J. Clin. Endocrinol. Metab. 89, 1117-1123 (2004).
Delmas PD, Vrijns B, Roux C et al. Reinforcement message based on bone turnover marker response influences long-term persistence with risedronate in osteoporosis: the IMPACT study. J. Bone Miner. Res. 18(Suppl. 2), S374 (2003).
Rubin SM, Cummings SR. Results of bone densitometry affect women's decision about taking measures to prevent fractures. Ann. Intern. Med. 116, 990-995 (1992).
Yasin S. Detecting and improving compliance: is concordance the solution? Aust. Fam. Physician 27, 255-260 (1998).
Hughes CM. Medication non-adherence in the elderly: how big is the problem? Drugs Aging 21, 793-811 (2004).
Wilson SR, Strub P, Buist AS et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am. J. Respir. Crit. Care Med. 181, 566-577 (2010).
Lewiecki EM, Babbitt AM, Piziak VK, Ozturk ZE, Bone HG. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation. Clin. Ther. 30, 605-621 (2008).
Faught E, Duh MS, Weiner JR et al. Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM study. Neurology 71, 1572-1578 (2008).
Faught RE, weiner JR, Guerin A et al. Impact of nonadherence to antiepileptic drugs in healthcare utilization and costs: findings from the RANSOM study. Epilepsia 50, 501-509 (2009).
Lage MJ, Hassan MK. The relationship between antipsychotic medicaton adherence and patient outcomes among individuals diagnosed with bipolar disorder: a retrospective study. Ann. Gen. Psychiatry 8, 7 (2009).
Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 43, 521-530 (2005).
Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am. J. Med. 114, 39-43 (2003).
Ho PM, Spertus JA, Masoudi FA et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch. Intern. Med. 166, 1842-1847 (2006).
Ho PM, Magid DJ, Shetterly SM et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am. Heart J. 155, 772-779 (2008).
Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation 117, 1028-1036 (2008).
Body JJ. Update on treatment of postmenopausal osteoporosis. Rev. Med. Brux. 29, 301-309 (2008).
Earnshaw SR, Graham CN, Ettinger B, Amonkar MM, Lynch NO, Middelhoven H. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates. Curr. Med. Res. Opin. 23, 2517-2529 (2007).
Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am. J. Med. 119, S25-S31 (2006).
Haynes RB, Yao X, Degani A et al. Interventions to enhance medication adherence. Cochrane Database Syst. Rev. (4), CD000011 (2005).
Bosmans JE, Brook OH, van Hout HP et al. Cost effectiveness of a pharmacy-based coaching programme to improve adherence to antidepressants. Pharmacoeconomics 25, 25-37 (2007).
Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J. Clin. Hypertens. 10, 348-354 (2008).
Curtis JR, Xi J, Westfall AO et al. Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med. Care 47, 334-341 (2009).
Body JJ, Bergmann P, Boonen S et al. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos. Int. 21(10), 1657-1680 (2010).
Andrade SE, Majumdar SR, Chan KA et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch. Intern. Med. 163, 2052-2057 (2003).
Gardner MJ, Flik KR, Mooar P, Lane JM. Improvement in the undertreatment of osteoporosis following hip fracture. J. Bone Joint Surg. Am. 84-A(8), 1342-1348 (2002).
Panneman MJ, Lips P, Sen SS, Herings RM. Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos. Int. 15, 120-124 (2004).
Freedman KB, Kaplan FS, Bilker WB et al. Treatment of osteoporosis: are physicians missing an opportunity? J. Bone Joint Surg. Am. 82-A(8), 1063-1070 (2000).
World Health Organization. Adherence to long-term therapies. Evidence for action (2003) www.who.int/chp/knowledge/publications/ adherence-report/en/